Literature DB >> 17410121

Pharmacokinetics of quetiapine in overdose and the effect of activated charcoal.

G K Isbister1, L E Friberg, L P Hackett, S B Duffull.   

Abstract

The aim of the study was to investigate the pharmacokinetics of quetiapine overdose and the effect of charcoal. The data set included 204 concentration-time points from 54 quetiapine overdose events (median dose 2,700 mg (300-24,000 mg)). Charcoal was administered 0.5-6 h after 19 overdoses. A fully Bayesian methodology for population pharmacokinetic analysis was used and data were modelled using WinBUGS. Uncertainty in the dose history was considered in model building by estimating dose amount and dose time within a possible range. Inclusion of informative priors stabilized the model and population parameter values could be estimated well. A one-compartment model with first-order input and first-order elimination described the data. The final model included uncertainty in dose time. The median and interquartile range of the half-life for individual patients was 6.6 h (4.9-8.4 h). Charcoal was estimated to reduce fraction absorbed by 35%. Co-ingested CYP3A4 inhibitors appeared to decrease clearance and CYP3A4 inducers increase clearance. Charcoal administration may be beneficial after quetiapine overdose.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17410121     DOI: 10.1038/sj.clpt.6100193

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Patterns of toxicity and factors influencing severity in acute adult trimipramine poisoning.

Authors:  Karen Gutscher; Christine Rauber-Lüthy; Marina Haller; Michèle Braun; Hugo Kupferschmidt; Gerd A Kullak-Ublick; Alessandro Ceschi
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  The pharmacokinetics of sertraline in overdose and the effect of activated charcoal.

Authors:  Joyce M Cooper; Stephen B Duffull; Ana S Saiao; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

3.  Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal.

Authors:  Freek van Gorp; Stephen Duffull; L Peter Hackett; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

4.  Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.

Authors:  Vidya Perera; Robert R Bies; Gary Mo; Michael J Dolton; Vaughan J Carr; Andrew J McLachlan; Richard O Day; Thomas M Polasek; Alan Forrest
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

5.  The Use of Activated Charcoal to Treat Intoxications.

Authors:  Tobias Zellner; Dagmar Prasa; Elke Färber; Petra Hoffmann-Walbeck; Dieter Genser; Florian Eyer
Journal:  Dtsch Arztebl Int       Date:  2019-05-03       Impact factor: 5.594

Review 6.  Activated charcoal for acute overdose: a reappraisal.

Authors:  David N Juurlink
Journal:  Br J Clin Pharmacol       Date:  2015-11-09       Impact factor: 4.335

7.  Electrocardiogram changes and arrhythmias in venlafaxine overdose.

Authors:  Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2009-02-02       Impact factor: 4.335

Review 8.  Activated charcoal for acute poisoning: one toxicologist's journey.

Authors:  Kent R Olson
Journal:  J Med Toxicol       Date:  2010-06

9.  Mirtazapine overdose is unlikely to cause major toxicity.

Authors:  I Berling; G K Isbister
Journal:  Clin Toxicol (Phila)       Date:  2013-11-14       Impact factor: 4.467

10.  Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

Authors:  Xiaoli Wang; Sabiha Mondal; Jessie Wang; Giridhar Tirucherai; Donglu Zhang; Rebecca A Boyd; Charles Frost
Journal:  Am J Cardiovasc Drugs       Date:  2014-04       Impact factor: 3.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.